-+ 0.00%
-+ 0.00%
-+ 0.00%

Pila Pharma Wins EU Nod for Trial Testing Erythromelalgia Drug in Obese Participants

MT Newswires·08/18/2026 06:16:12
Listen to the news
06:16 AM EDT, 08/18/2026 (MT Newswires) -- Sweden-based Pila Pharma (PILA.ST) secured approval from the European Medicines Agency to carry out a two-part trial assessing its erythromelalgia drug candidate in obese participants. The 12‑week PP-CT04 trial will test a within-subject dose titration approach aimed at reaching therapeutic plasma concentrations of XEN-D0501 not previously investigated, according to a Tuesday release. Dosing will be escalated on an individual basis, starting at 4 milligrams twice daily and will increase stepwise to up to 16 mg twice daily, which will be administered for one week to up to four weeks. Once a participant's maximum tolerable dose is confirmed to be tolerable, they will stay on that dose for an eight-week maintenance period.